Abstract:Background & Objectives: Acute Respiratory Distress Syndrome (ARDS) is common and frequently fatal condition characterized by overwhelming inflammation. Resolution of inflammation is an active biological process regulated by endogenous specialized lipid mediators including resolvins. Fibroblasts, farfrom being matrix-producing reparative cells, could exhibit specific function in resolution. Cyclooxygenase-2(COX-2) is inducible by inflammatory stimuli and was reported to drive inflammation by peaking in onset of inflammation as well as resolve inflammation with maximal expression in resolution phase. Interestingly, Resolvin D1 (RvD1) plays a biphasic role on both peaks of COX-2 to exert its anti-inflammation and pro-resolution actions. In this study, we aim to work out the underlying mechanism for RvD1 promoting COX-2 expression in regulating inflammatory resolution in fibroblasts. Materials & Methods: Pulmonary fibroblasts were isolated from Sprague-Dawley rats and cultured for 48 h with 1μg/ml LPS (lipopolysaccharide) and/or 100nM RvD1.The expression of COX-2,nuclear NF-κB protein (P65,P50,RelB) were measured by western blot, the activation of NF-kB was assessed by Electrophoretic mobility-gel shift assay (EMSA) and supershift. Results: After incubated with LPS for 48h, fibroblasts were treated with inhibitors of P38MARK (SB203580), JNK (SP600125), NF-κB (MG-132) pathways involved in regulation COX-2 expression, only NF-κB inhibitor inhibited COX-2 expression compared to LPS group (P<0.01,n=6). NF-κB was activated in fibroblasts with LPS challenged and only P50/P50 homodimer was activated after LPS stimulated 48h with the assessment of EMSA, supershift and nuclear protein western blot, whereas there was no significant change in P65 and RelB subunits between control and LPS group.RvD1 further promoted the P50 nuclear translocation and DNA binding activation with LPS incubated for 48h(P<0.05, n=8). Moreover, the RvD1 effects on COX-2 resolving expression in fibroblasts was abrogated when P50 knockout and the COX-2 level in P50-/- fibroblasts was much lower than that in wildtype ones after LPS stimulated 48h (P<0.001, n=4). Conclusion: RvD1-derived promotion of COX-2 expression is beneficial for complete resolution of inflammation, which is partly through activated NF-κB P50/P50 homodimer.As timely inflammatory resolution is essential for host homeostasis, RvD1 might have therapeutic potential in the management of ARDS. References: 1. Wu D, Zheng S, Li W, Yang L, Liu Y, Zheng X, Yang Y, Yang L, Wang Q, Smith FG et al: Novel biphasic role of resolvin D1 on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts is partly through PI3K/AKT and ERK2 pathways. Mediators of inflammation 2013, 2013:964012. Disclosure of Interest: None declared

Resolvin D1, therapeutic target in acute respiratory distress syndrome

Protective Actions of Aspirin-Triggered (17R) Resolvin D1 and Its Analogue, 17R-Hydroxy-19-para-fluorophenoxy-resolvin D1 Methyl Ester, in C5a-Dependent IgG Immune Complex–Induced Inflammation and Lung Injury

Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome

RvD1 ameliorates LPS-induced acute lung injury via the suppression of neutrophil infiltration by reducing CXCL2 expression and release from resident alveolar macrophages

Pro-Resolving Mediator Resolvin E1 Restores Alveolar Fluid Clearance in Acute Respiratory Distress Syndrome

Resolvin D1 Attenuates Lung Inflammation in LPS Induced-Ali Partly Through PPARγ/NF-κB Pathway

Abstract PR099: Resolvin D1 Improves the Resolution of Inflammation Via Activation P50/P50-Mediated Cyclooxygenase-2 Expression in Fibroblasts.

Resolvin D1 attenuates lipopolysaccharide induced acute lung injury through CXCL-12/CXCR4 pathway.

Resolvin D1 Protects Mice from LPS-induced Acute Lung Injury

Resolvin D1 Attenuates Inflammation In Lipopolysaccharide-Induced Acute Lung Injury Through A Process Involving The Ppar Gamma/Nf-Kappa B Pathway

Lung Inflammation Resolution by RvD1 and RvD2 in a Receptor-Dependent Manner

Resolvind1 Reduces Apoptosis and Inflammation in Primary Human Alveolar Epithelial Type 2 Cells

Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway

Resolvin D4 mitigates lipopolysaccharide-induced lung injury in mice

Resolvin D1 Attenuates Ventilator-Induced Lung Injury by Reducing HMGB1 Release in a HO-1-dependent Pathway.

Resolvin D1 Alleviates Ventilator-Induced Lung Injury in Mice by Activating PPARγ/NF-κB Signaling Pathway

Resolvin D1 binds human phagocytes with evidence for proresolving receptors

Resolvin D1 (Rvd1) Attenuates In Vitro LPS-Stimulated Inflammation Through Downregulation of miR-155, miR -146, miR -148 and Krupple Like Factor 5

Resolvin D1 prevents injurious neutrophil swarming in transplanted lungs

RvD1 improves resident alveolar macrophage self-renewal via the ALX/MAPK14/S100A8/A9 pathway in acute respiratory distress syndrome

The role of Resolvin D1 in liver diseases